Improvements in cardiometabolic markers, including blood pressure, lipid profiles, and glycaemic parameters, were also observed
doi: 10.1002/alz.12638 113 QiuCKivipeltoMvon StraussE
While tirzepatide is a gold-standard diabetes treatment right now, retatrutides multi-pathway profile suggests it could offer an equally powerful, if not uniquely specialized, alternative for severe insulin resistance and advanced metabolic syndrome once approved
Mazdutide Development Pipeline Higher-dose Mazdutide formulations under investigation may close the efficacy gap with Retatrutide while maintaining tolerability advantages
Understanding the long-term picture helps set realistic expectations
Dose exposure: starting weight matters A lighter body has less blood and tissue in which to distribute the same dose, leaving more retatrutide available to reach receptors